Clinical Trials
3 trialsNCT01931098 2025-08-11
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03275558 2018-07-19
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
Center Trials & Treatment
Phase 1 Withdrawn
NCT00459381 2017-03-15
Pazopanib in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Completed